Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward?
Infect Dis Now
; 54(4): 104918, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38636842
ABSTRACT
PURPOSE:
We evaluated the interest of systematic screening of serum fungal markers in patients hospitalized in a medical ward.METHODS:
We retrospectively analyzed all patients hospitalized in our infectious disease department from October 1st to October 31st, 2020 for COVID-19 without prior ICU admission, and for whom systematic screening of serum fungal markers was performed.RESULTS:
Thirty patients were included. The majority of patients received corticosteroids (96.7%). The galactomannan antigen assay was positive for 1/30 patients at D0, and 0/24, 0/16, 0/13 and 0/2 at D4, D7, D10 and D14 respectively. 1,3-ß-D-glucan was positive for 0/30, 1/24, 1/12, 0/12, 0/2 at D0, D4, D7, D10 and D14 respectively. No Aspergillus fumigatus PCR was positive. No cases of aspergillosis were retained.CONCLUSION:
Our study does not support the interest of systematic screening of fungal markers in immunocompetent patients with COVID-19 in a conventional unit.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aspergilose
/
Biomarcadores
/
Beta-Glucanas
/
Galactose
/
COVID-19
/
Mananas
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Infect Dis Now
Ano de publicação:
2024
Tipo de documento:
Article